Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
11
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Brian Henick, MD

Collaborators